Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
2.200
+0.140 (6.80%)
Nov 21, 2024, 11:21 AM EST - Market open
Cocrystal Pharma Employees
Cocrystal Pharma had 12 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,558,500
Market Cap
22.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Bionano Genomics | 344 |
Bolt Biotherapeutics | 100 |
Pieris Pharmaceuticals | 50 |
VSee Health | 40 |
NeurAxis | 19 |
NeuroSense Therapeutics | 18 |
BriaCell Therapeutics | 16 |
NeuroOne Medical Technologies | 16 |
COCP News
- 3 months ago - Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences - GlobeNewsWire
- 3 months ago - CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 6 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 7 months ago - Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - GlobeNewsWire
- 8 months ago - Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 8 months ago - Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A - GlobeNewsWire
- 9 months ago - Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - Accesswire
- 1 year ago - Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A - GlobeNewsWire